Tanja Obradovic: Very dynamic day at ASCO2024

Tanja Obradovic shared a post on LinkedIn:

“Very dynamic ASCO2024 day as we learned quite a few updates, especially in NSCLC around advances targeted therapies and novel ADCs are making and many of those in the early space but attention was really upon late-stage results. In the late development space were updates on very active TROP-2-directed ADCs and sacituzumab govitecan (SG).

Unfortunately following TROP-2 SG failure in confirmatory TROPiCS-04 study in locally advanced or metastatic urothelial cancer (therefore possibly facing withdrawal), results from the EVOKE-01 study evaluating the SG in pretreated metastatic non-small cell lung cancer versus docetaxel showed a poor two-month survival benefit compared with docetaxel chemotherapy in the control arm. So, it remains to be seen where TROP-2-directed ADCs will land.

Following all of the ASCO2024 developments and welcoming all for discussion is also ICON plc Biotech team at booth 30119. Here is a photo of me today with great colleagues Sarah Peters and Bea Mann.”

Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.